Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.100
+0.230 (12.30%)
At close: Jun 26, 2026, 4:00 PM EDT
2.130
+0.030 (1.43%)
Pre-market: Jun 29, 2026, 4:13 AM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$39,230
Profits / Employee
-$806,876
Market Cap
244.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Coherus Oncology | 145 |
| Nautilus Biotechnology | 127 |
| AC Immune | 122 |
| Invivyd | 122 |
| Foghorn Therapeutics | 106 |
| Orchestra BioMed Holdings | 86 |
| Fulcrum Therapeutics | 55 |
FATE News
- 13 days ago - Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewsWire
- 24 days ago - Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - GlobeNewsWire
- 25 days ago - Fate Therapeutics management to meet with Piper Sandler - TheFly
- 25 days ago - Fate Therapeutics Slides: Corporate presentation - Filings
- 26 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Fate Therapeutics price target raised to $2.20 from $2 at BofA - TheFly
- 5 weeks ago - Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - GlobeNewsWire